Clinical trial
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
NCT00293059 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00293059 |
|---|---|
| Title | Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding |
| Official title | A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding. |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metrorrhagia |
| Intervention type | Drug |
| Interventions | Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027), Placebo |
| Enrollment | 190 |
| Start date | Dec 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Feb 17, 2006 |
| Last update posted | Nov 27, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: